What is Mitochon Pharmaceuticals?
Mitochon Pharmaceuticals, founded in 2014, is a biotech business focused on developing medications that target the mitochondria for a variety of critical diseases with high unmet medical needs. Huntington’s Disease, Multiple Sclerosis/Optic Neuritis, Wolfram Syndrome, Epilepsy, Traumatic Brain Injury (TBI), Duchenne Muscular Dystrophy (DMD), Alzheimer’s Disease, and Parkinson Disease are among the disorders that our development initiatives are largely focused on. These disorders have been linked to numerous mitochondrial abnormalities, according to ongoing studies. Mitochon intends to repair these, paving the path for a wide spectrum of disease-modifying medicines. Mitochon is driven by a group of industry leaders with more than 100 years of combined experience and a desire for developing breakthrough medicinal solutions for a variety of diseases that are difficult to treat.
The mitochondria are the cells’ “powerhouses,” producing ATP (adenosine triphosphate), the universal energy storage, from the food we ingest. After ATP is created, it is used to power a variety of cellular operations throughout the body. These one-of-a-kind organelles can fail, resulting in the terrible diseases we’re trying to prevent.
Their objective is to develop meaningful medications that function at the root of creeping diseases by modulating the physiology of mitochondria to slow disease development. The pleiotropic cascade effect of altering this entire organelle’s physiology by tiny increases in energy expenditure results in improved cellular function increased neuroprotection/growth biomarkers, and a reduction in a disease state, according to a major premise of their approach. This has been demonstrated numerous times in energy expenditure models. Data now exists to show improvements in cognition with Alzheimer’s Disease (Liu, D. 2014 & Geisler, J. 2017), reduction in symptoms associated with Huntington’s Disease (Duan, W. 2003 & Wu, B. 2017), reduction in reactive oxygen species associated with ALS, improve lipid profiles affecting diabetes/heart disease (Samuel, V. 2004 & Perry, RJ 2013), and neuropathic pain (Samuel, V. 2004 (Pettigrew, C 2012). Overall, increasing energy expenditure via mitochondrial modulation can have disease-modifying effects, even at weight-neutral or weight-preserving levels.
Robert Alonso, Founder & CEO
He has worked at both large pharmaceutical businesses (Merck and Roche) and tiny biotech companies for the past 25 years (Ceptaris). Mr. Alonso most recently launched Ceptaris Therapeutics, where he generated more than $40 million in venture funding and successfully guided the lead program through phase III testing and NDA filing (Approval was received in 2013). Ceptaris was acquired by Actelion Pharmaceuticals in 2013. Mr. Alonso is a seasoned executive with extensive experience in licensing and other business transactions, including raising venture financing and negotiating deals worth more than $500 million. He has successfully brought many medications through the Investigational New Drug (IND) process and one through the New Drug Application procedure (NDA). Mr. Alonso is the inventor of nine patents that have been issued. Mr. Alonso earned a bachelor’s degree from Boston College and a master’s degree in entrepreneurship from Babson College.
What do they believe in?
They believe that the lack of breakthroughs for a variety of neuromuscular and neurodegenerative diseases, as well as attempts to resolve the “over-nutritional phenotype” that leads to metabolic disorders, is due to investigations focusing on downstream events, when the problem may be upstream at the mitochondria. Their recent findings imply that very low, non-toxic doses of mitochondrial modulators could be the key to delaying or stopping disease development. Their goal is to build this platform for the treatment of sneaky diseases and to pave the way for breakthroughs in areas where there is a great deal of unmet medical need.
What is their need?
Overt ROS production, calcium (Ca2+) overload, diminished neurotrophins, increased cell death, and mitochondrial malfunction are all prevalent features of neurodegenerative disorders, and there are currently no viable treatments. They believe that a pharmaceutical intervention that eliminates ROS production, reduces Ca2+ overload, up-regulates neurotrophins, and enhances the mitochondrial population’s quality by culling poor-functioning mitochondria would be a “disease-modifying” therapy. Huntington’s Disease, Wolfram Syndrome, Optic Neuritis, Alzheimer’s Disease, Lou Gehrig’s Disease (ALS), Parkinson’s Disease, Traumatic Brain Injury (TBI), stroke recovery, and other diseases associated with high cellular stress currently have no effective treatments, so their sole goal is to resolve this issue as quickly as possible.
Website : https://www.mitochonpharma.com/
Industry : Biotechnology
Company size : 2-10 employees
Headquarters : Blue Bell, Pennsylvania
Type : Privately Held
Founded : 2014